Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS
Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS
Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS
Infectious disease professionals, bracing for an overhaul of the CDC’s vaccine advisory group, are in discussions to stand up a parallel committee of experts outside
Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS
Plus, news about Recursion, Nxera, Viatris and DualityBio: Pacira BioSciences takes on GQ Bio: The non-opioid pain biotech is Sign up to read this article
The second blank-check vehicle from Cormorant’s Bihua Chen plans to take BridgeBio’s oncology spinout onto the Nasdaq. The special purpose acquisition company — known as
Jill Wood had pinned her hopes on a little-known federal program to fund her son’s gene therapy. The initiative, which awards vouchers to companies targeting
Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS
Another day, another molecular glue deal in the biopharma world. This time around, it’s Eli Lilly partnering with the private startup Magnet Biomedicine on the